AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12171669 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial syphilis screening using rapid plasma reagin or Venereal Disease Research Laboratory tests, confirmed by fluorescent treponemal antibody absorption.
Number of subjects: 0
Study 12171669 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine syphilis testing after delivery.
Number of subjects: 0
Study 12171669 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation for a second routine test for syphilis early in the third trimester.
Number of subjects: 0
Study 10530094 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D action with an additional pulsating movement
Number of subjects: 32
Study 10530094 — intervention group
Group type: COMPARATOR
Intervention: D9 oscillating/rotating action
Number of subjects: 32
Study 8078449 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition support
Number of subjects: 0
Study 8078449 — intervention group
Group type: COMPARATOR
Intervention: Nutrition therapy
Number of subjects: 0
Study 2815968 — intervention group
Group type: EXPERIMENTAL
Intervention: Suckling mouse brain rabies vaccine with equine hyperimmune serum (40 IU per kg body weight)
Number of subjects: 50
Study 2815968 — intervention group
Group type: EXPERIMENTAL
Intervention: Suckling mouse brain rabies vaccine without equine hyperimmune serum
Number of subjects: 50
Study 16799 — intervention group
Group type: COMPARATOR
Intervention: Nefopam HCl + Placebo
Number of subjects: 45
Study 16799 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam HCl + Codeine
Number of subjects: 45
Study 16799 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam HCl + Pentazocine
Number of subjects: 45
Study 16799 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam HCl + Propoxyphene
Number of subjects: 45
Study 16799 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam HCl
Number of subjects: 45
Study 31972826 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load (HL) resistance exercise (5 repetitions at 85% 1RM)
Number of subjects: 15
Study 31972826 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow-restricted (BFR) resistance exercise (30 repetitions at 30% 1RM)
Number of subjects: 15
Study 31613689 — intervention group
Group type: COMPARATOR
Intervention: Conventional Laparoscopic Appendectomy (CLA)
Number of subjects: 147
Study 31613689 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Port Laparoscopic Appendectomy (SPLA)
Number of subjects: 147
Study 31613689 — intervention group
Group type: COMPARATOR
Intervention: Both approaches (CLA and SPLA)
Number of subjects: 147
Study 28184045 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group with inhaler labels (ACCa; THa)
Number of subjects: 95
Study 28184045 — intervention group
Group type: COMPARATOR
Intervention: Control group without inhaler labels (ACCc; THc)
Number of subjects: 95
Study 25939894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide 2000 mg 1×/week i.v. (CIL-once)
Number of subjects: 169
Study 25939894 — intervention group
Group type: COMPARATOR
Intervention: Control (cetuximab plus platinum-based chemotherapy)
Number of subjects: 169
Study 22735311 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG with fibrin glue
Number of subjects: 20
Study 22735311 — intervention group
Group type: COMPARATOR
Intervention: CAG with patients' own blood
Number of subjects: 20
Study 21886035 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation video (SIM)
Number of subjects: 239
Study 21886035 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further intervention)
Number of subjects: 239
Study 18593517 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ (160/12.5 mg, titrated to 160/25 mg after 2 weeks and to 320/25 mg after 4 weeks)
Number of subjects: 608
Study 18593517 — intervention group
Group type: COMPARATOR
Intervention: Valsartan monotherapy (160 mg, titrated to 320 mg after 2 weeks and sham-titrated to 320 mg after 4 weeks)
Number of subjects: 608
Study 18593517 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ
Number of subjects: 608
Study 18593517 — intervention group
Group type: COMPARATOR
Intervention: Valsartan monotherapy
Number of subjects: 608
Study 16295261 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in research aimed at determining treatment effectiveness
Number of subjects: 0
Study 16295261 — intervention group
Group type: COMPARATOR
Intervention: Established treatments
Number of subjects: 0
Study 12232450 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (Oxis) Turbuhaler plus Budesonide (Pulmicort) Turbuhaler
Number of subjects: 0
Study 12232450 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (Pulmicort) Turbuhaler alone
Number of subjects: 0
Study 12232450 — intervention group
Group type: COMPARATOR
Intervention: Noncorticosteroid treatment (control group)
Number of subjects: 0
Study 10406361 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention by an old-age psychiatry hospital outreach team, including seminars and weekly visits from a psychiatric nurse over 6 months.
Number of subjects: 120
Study 10406361 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 120
Study 7752637 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 3977
Study 7752637 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 3977
Study 7752637 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants identifying as former or recovering alcoholics
Number of subjects: 3977
Study 7752637 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge drinking
Number of subjects: 3977
Study 1979494 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug A (propyphenazone 250 mg, ethylmorphine 5 mg, caffeine 5 mg)
Number of subjects: 10
Study 1979494 — intervention group
Group type: COMPARATOR
Intervention: Drug B (dipyrone 500 mg, diphenhydramine 12.5 mg, adiphenine 5 mg, ethyl aminobenzoate 2.5 mg)
Number of subjects: 10
Study 375943 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-phenylephrine hydrochloride gel
Number of subjects: 12
Study 375943 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 12
Study 28960542 — intervention group
Group type: EXPERIMENTAL
Intervention: 18‐week supervised exercise programme
Number of subjects: 50
Study 27614727 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 215
Study 27614727 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 215
Study 22968626 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene
Number of subjects: 253
Study 22968626 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 253
Study 23521375 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course antenatal zidovudine (ZDV)
Number of subjects: 159
Study 23521375 — intervention group
Group type: COMPARATOR
Intervention: Single-dose nevirapine (sdNVP)
Number of subjects: 159
Study 20687401 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-and-parent group (N = 23)
Number of subjects: 42
Study 20687401 — intervention group
Group type: COMPARATOR
Intervention: Child-alone group (N = 19)
Number of subjects: 42
Study 18691796 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio tone guidance (low-pitched sound every 0.6 s for chest compression guidance and high-pitched sound every 10 deliveries for ventilation guidance at 6s intervals)
Number of subjects: 80
Study 18691796 — intervention group
Group type: COMPARATOR
Intervention: No feedback (control group)
Number of subjects: 80
Study 15757015 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/d for 2 years and 10 mg/d thereafter
Number of subjects: 3737
Study 15757015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3737
Study 12618160 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg)
Number of subjects: 1008
Study 12618160 — intervention group
Group type: COMPARATOR
Intervention: Continuous combined hormone replacement therapy (2 mg 17beta‐oestradiol and 1 mg norethisterone acetate)
Number of subjects: 1008
Study 10693159 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 56
Study 10693159 — intervention group
Group type: COMPARATOR
Intervention: haloperidol
Number of subjects: 56
Study 9350383 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral zolmitriptan
Number of subjects: 12
Study 9350383 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oral ergotamine
Number of subjects: 12
Study 9350383 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of zolmitriptan and ergotamine
Number of subjects: 12
Study 9350383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8363027 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.5 mg/kg)
Number of subjects: 60
Study 8363027 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.3 mg/kg)
Number of subjects: 60
Study 8363027 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.15 mg/kg)
Number of subjects: 60
Study 3079695 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose misoprostol
Number of subjects: 45
Study 3079695 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose misoprostol
Number of subjects: 45
Study 3079695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 29717288 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 5 mg
Number of subjects: 50
Study 29717288 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 5 mg plus dexmedetomidine 5 µg intrathecally
Number of subjects: 50
Study 27294328 — intervention group
Group type: EXPERIMENTAL
Intervention: Running at 55%, 65%, and 75% maximal oxygen consumption for 30 minutes
Number of subjects: 10
Study 27294328 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery after exercise
Number of subjects: 10
Study 27294328 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (all intensities)
Number of subjects: 10
Study 27294328 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery (after exercise)
Number of subjects: 10
Study 24893325 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert guided mentorship session (20 minutes)
Number of subjects: 50
Study 24893325 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 50
Study 24893325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (regardless of randomization)
Number of subjects: 50
Study 22579428 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupressure
Number of subjects: 109
Study 22579428 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo acupressure
Number of subjects: 109
Study 22579428 — intervention group
Group type: COMPARATOR
Intervention: Relaxation CD control
Number of subjects: 109
Study 20215759 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group 1 (LI 11)
Number of subjects: 60
Study 20215759 — intervention group
Group type: COMPARATOR
Intervention: Relaxation group (control)
Number of subjects: 60
Study 20215759 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture groups (1 and 2)
Number of subjects: 60
Study 18514303 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine plus axitinib (1000 mg/m² plus 5 mg twice daily)
Number of subjects: 103
Study 18514303 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine alone (1000 mg/m²)
Number of subjects: 103
Study 18514303 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine plus axitinib
Number of subjects: 103
Study 18514303 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine alone
Number of subjects: 103
Study 15843280 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 19
Study 15843280 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 19
Study 11800503 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 50 mg o.d.
Number of subjects: 272
Study 11800503 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine 20 mg o.d.
Number of subjects: 272
Study 10650023 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient hysteroscopy
Number of subjects: 100
Study 10650023 — intervention group
Group type: COMPARATOR
Intervention: Day case hysteroscopy
Number of subjects: 100
Study 10650023 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 8645650 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin depot treatment for 8 weeks before endometrial resection
Number of subjects: 71
Study 8645650 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery without pretreatment
Number of subjects: 71
Study 8645650 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin treatment in women with adenomyosis
Number of subjects: 71
Study 1534364 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined bacterial and viral infection
Number of subjects: 271
Study 1534364 — intervention group
Group type: COMPARATOR
Intervention: Only bacterial otitis
Number of subjects: 271
Study 1534364 — intervention group
Group type: COMPARATOR
Intervention: Only viral infection
Number of subjects: 271
Study 1534364 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus in middle ear fluid
Number of subjects: 271
Study 1534364 — intervention group
Group type: COMPARATOR
Intervention: Virus only in nasal wash specimens or diagnosed by serologic studies
Number of subjects: 271
Study 2410224 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral application of a tone burst stimulus
Number of subjects: 0
Study 31648967 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI sequences
Number of subjects: 55
Study 31648967 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI+FLAIR sequences in combination
Number of subjects: 55
Study 28834008 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia
Number of subjects: 0
Study 28834008 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia (in patients aged <40 years)
Number of subjects: 0
Study 28834008 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia (duration <4 years)
Number of subjects: 0
Study 28834008 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia (duration 4 to 8 years)
Number of subjects: 0
Study 28834008 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia (duration >8 years)
Number of subjects: 0
Study 28834008 — intervention group
Group type: COMPARATOR
Intervention: Patients with insomnia
Number of subjects: 0
Study 27094007 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermometry plus mHealth (SMS and voice messaging)
Number of subjects: 0
Study 27094007 — intervention group
Group type: COMPARATOR
Intervention: Thermometry alone
Number of subjects: 0
Study 22414889 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available weight-loss regimen
Number of subjects: 45
Study 22414889 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupported dieting
Number of subjects: 45
Study 22414889 — intervention group
Group type: COMPARATOR
Intervention: Non-dieting control group
Number of subjects: 45
Study 21270715 — intervention group
Group type: COMPARATOR
Intervention: Surgical intervention for diabetic patients with IDH
Number of subjects: 199
Study 21270715 — intervention group
Group type: COMPARATOR
Intervention: Surgical intervention for diabetic patients with SpS
Number of subjects: 199
Study 21270715 — intervention group
Group type: COMPARATOR
Intervention: Surgical intervention for diabetic patients with DS
Number of subjects: 199
Study 21270715 — intervention group
Group type: COMPARATOR
Intervention: Surgical intervention for nondiabetic patients with SpS
Number of subjects: 199
Study 21270715 — intervention group
Group type: COMPARATOR
Intervention: Postoperative complications in diabetic patients with SpS
Number of subjects: 199
Study 21270715 — intervention group
Group type: COMPARATOR
Intervention: Blood replacement in diabetic patients with DS
Number of subjects: 199
Study 19386624 — intervention group
Group type: EXPERIMENTAL
Intervention: Assigned prenatal multivitamins
Number of subjects: 70
Study 19386624 — intervention group
Group type: COMPARATOR
Intervention: Previous multivitamins
Number of subjects: 70
Study 19386624 — intervention group
Group type: EXPERIMENTAL
Intervention: Assigned prenatal multivitamins (for those who never took them)
Number of subjects: 70
Study 16708045 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls on the Move program (individually tailored computerized physical activity program plus nurse counseling)
Number of subjects: 77
Study 16708045 — intervention group
Group type: COMPARATOR
Intervention: Control group (received a handout listing physical activity recommendations)
Number of subjects: 77
Study 15262844 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SESs)
Number of subjects: 1058
Study 15262844 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 1058
Study 11696804 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 0.2 mg
Number of subjects: 193
Study 11696804 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 0.4 mg
Number of subjects: 193
Study 11696804 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 0.6 mg
Number of subjects: 193
Study 11696804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 9151010 — intervention group
Group type: EXPERIMENTAL
Intervention: External hip protectors
Number of subjects: 247
Study 7953039 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention including monthly 45-minute counselling sessions focused on management of social and occupational problems, medication management, family education, family group meetings, and crisis intervention.
Number of subjects: 63
Study 7953039 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 63
Study 7953039 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention
Number of subjects: 63
Study 3069568 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g i.v. Cefotetan
Number of subjects: 144
Study 3069568 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 144
Study 29242972 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic surgery
Number of subjects: 51
Study 29242972 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 51
Study 27032449 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based problem solving therapy with weekly student support (n=136)
Number of subjects: 269
Study 27032449 — intervention group
Group type: COMPARATOR
Intervention: Control group with self-help booklet (n=133)
Number of subjects: 269
Study 27032449 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based problem solving therapy (n=136)
Number of subjects: 269
Study 24173623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg to a maximum of 200 mg/day
Number of subjects: 38
Study 24173623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 24173623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (in subset meeting DSM-IV criteria)
Number of subjects: 38
Study 23690416 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm (chemotherapy based on ERCC1 and RRM1 levels)
Number of subjects: 275
Study 23690416 — intervention group
Group type: COMPARATOR
Intervention: Control arm (gemcitabine/carboplatin)
Number of subjects: 275
Study 20569705 — intervention group
Group type: EXPERIMENTAL
Intervention: Carperitide treatment (69.4%)
Number of subjects: 0
Study 20569705 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers (53.9%)
Number of subjects: 0
Study 20569705 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital stay
Number of subjects: 0
Study 20569705 — intervention group
Group type: EXPERIMENTAL
Intervention: Readmission rate
Number of subjects: 0
Study 18157994 — intervention group
Group type: EXPERIMENTAL
Intervention: SDM group (physicians trained in SDM communication, access to computer-based information package)
Number of subjects: 85
Study 18157994 — intervention group
Group type: COMPARATOR
Intervention: Information-only group (standard physicians, only received information package)
Number of subjects: 85
Study 20453720 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-delivered therapy (PDPT)
Number of subjects: 484
Study 20453720 — intervention group
Group type: COMPARATOR
Intervention: Public health disease intervention (DIS)
Number of subjects: 484
Study 20453720 — intervention group
Group type: COMPARATOR
Intervention: Self-referral of partners (PR)
Number of subjects: 484
Study 16274808 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus retraining therapy (TRT)
Number of subjects: 158
Study 16274808 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 158
Study 16274808 — intervention group
Group type: COMPARATOR
Intervention: Partially treated group (patients that refused prosthesis adaptation)
Number of subjects: 158
Study 12111283 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly trained professional rugby players (RP)
Number of subjects: 36
Study 12111283 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly trained triathletes (TA)
Number of subjects: 36
Study 12111283 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 36
Study 9875635 — intervention group
Group type: EXPERIMENTAL
Intervention: HGV co-infection
Number of subjects: 89
Study 9875635 — intervention group
Group type: COMPARATOR
Intervention: HCV infection without HGV co-infection
Number of subjects: 89
Study 9875635 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 antibodies presence
Number of subjects: 89
Study 7979464 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.2 mg/kg three times a day for two weeks)
Number of subjects: 16
Study 7979464 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline equivalent volumes)
Number of subjects: 16
Study 2633666 — intervention group
Group type: EXPERIMENTAL
Intervention: Swan‐Ganz catheter with optic fibres emitting light characterized by three different wavelengths (Opticath Oximetrix)
Number of subjects: 19
Study 2633666 — intervention group
Group type: COMPARATOR
Intervention: Sat‐one Edwards catheter with two different wavelengths
Number of subjects: 19
Study 2633666 — intervention group
Group type: EXPERIMENTAL
Intervention: Oximetrix catheter
Number of subjects: 19
Study 2633666 — intervention group
Group type: COMPARATOR
Intervention: Edwards catheter
Number of subjects: 19